Acetyl-11-keto-β-boswellic acid (AKBA): Structure requirements for binding and 5-lipoxygenase inhibitory activity

British Journal of Pharmacology

Volumn 117, Issue 4, 1996, Pages 615-618

  Sailer, Eckart Roderich ^a   Subramanian, Lakshminarayanapuram R ^a   Rall, Beatrice ^a   Hoernlein, Rainer F ^a   Ammon, Hermann P T ^a   Safayhi, Hasan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

5 lipoxygenase; Amyrin; Antiinflammatory; Boswellic acid; Inflammation; Leukotriene synthesis inhibitor; Pentacyclic triterpene

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; BOSWELLIC ACID; TRITERPENE;

ANIMAL CELL; ARTICLE; CELL FREE SYSTEM; CONTROLLED STUDY; DEACETYLATION; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; ENZYME BINDING; ENZYME INHIBITION; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; REDUCTION;

EID: 0030070162     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15235.x     Document Type: Article

References (14)

1. 4 formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of Boswellia serrata. Planta Med., 57, 203-207.
2. BATT, D.G. (1992). 5-Lipoxygenase inhibitors and their anti-inflammatory activities. In Progress in Med. Chem., Vol. 29 ed. Ellis, G.P. & Luscombe, D.K. pp. 439-449. Amsterdam: Elsevier Sci. Publ. B.V.
3. FORD-HUTCHINSON, A.W. (1991). Potential and therapeutic value of development of 5-lipoxygenase inhibitors. In Leukotrienes and their products ed. Crooke, S.T. & Wong, A. pp. 137-160. San Diego: Academic Press.
4. FORD-HUTCHINSON, A.W., GRESSER, M. & YOUNG, R.N. (1994). 5-Lipoxygenase. Annu. Rev. Biochem., 63, 383-417.
5. HAGMANN, W., DENZLINGER, C. & KEPPLER, D. (1985). Production of leukotrienes in endotoxin shock. FEBS Lett., 180, 309-313.
6. HAGMANN, W. & KEPPLER, D. (1982). Leukotriene antagonists prevent endotoxin lethality. Naturwiss., 69, 594-595.
7. MCMILLAN, R.M. & WALKER, E.R.H (1992). Designing therapeutically effective 5-lipoxygenase inhibitors. Trends Pharmacol. Sci., 13, 323-330.
8. SAFAYHI, H., MACK, T. & AMMON, H.P.T. (1991). Protection by boswellic acids against galactosamine/endotoxin-induced hepatitis in mice. Biochem. Pharmacol., 41, 1536-1537.
9. SAFAYHI, H., MACK, T., SABIERAJ, J., ANAZODO, M.I., SUBRAMANIAN, L.R. & AMMON, H.P.T. (1992). Boswellic acids: Novel, specific, nonredox inhibitors of 5-lipoxygenase. J. Pharmacol. Exp. Ther., 261, 1143-1146.
10. SAFAYHI, H., SAILER, E.-R., AMMON, H.P.T. (1995). Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-β-boswellic acid. Mol. Pharmacol., 47, 1212-1216.
11. SAFAYHI, H., TIEGS, G. & WENDEL, A. (1985). A novel biologically active seleno-organic compound-V: Inhibition by Ebselen (PZ 51) of rat peritoneal neutrophil lipoxygenase. Biochem. Pharmacol., 34, 2691-2694.
12. WASSERMAN, M.A., SMITH III, E.F., UNDERWOOD, D.C. & BARNETTE, M.A. (1991). Pharmacology and pathophysiology of 5-lipoxygenase products. In Leukotrienes and their Products ed. Crooke, S.T. & Wong, A. pp. 1-50. San Diego: Academic Press.
13. WENDEL, A. & TIEGS, G. (1986). A novel biologically active seleno-organic compound-VI. Protection by Ebselen (PZ51) against galactosamine/endotoxin-induced hepatitis in mice. Biochem. Pharmacol., 35, 2115-2118.
14. WINTERSTEIN, A. & STEIN, G. (1932). Untersuchungen in der Saponinreihe. Zur Kenntnis der Mono-oxy-triterpensäuren. Hoppe-S. Z. Physiol. Chem., 208, 9-25.